Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abbott LaboratoriesXSWX:ABT +2.42%80 Equity-to-Asset is 0.47 as of Mar. 2026, which is at its 10-year median of 0.47. GuruFocus rates XSWX:ABT with a GF Score™ of 80/100 and a GF Value™ of CHF107.34. Among 852 Medical Devices & Instruments companies, Abbott Laboratories ranks worse than 69.95% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Abbott Laboratories's Total Stockholders Equity for the quarter that ended in Mar. 2026 was CHF40,988 Mil. Abbott Laboratories's Total Assets for the quarter that ended in Mar. 2026 was CHF86,941 Mil.
Therefore, Abbott Laboratories's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.47.
The historical rank and industry rank for Abbott Laboratories's Equity-to-Asset or its related term are showing as below:
XSWX:ABT'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.39 Med: 0.47 Max: 0.61
Current: 0.47
During the past 13 years, the highest Equity to Asset Ratio of Abbott Laboratories was 0.61. The lowest was 0.39. And the median was 0.47.
XSWX:ABT's Equity-to-Asset is ranked worse than 69.95% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.645
vs XSWX:ABT: 0.47
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Abbott Laboratories Equity-to-Asset Related Terms
Abbott Laboratories Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Abbott Laboratories's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ABT vs SYK, MDT, BSX: Equity-to-Asset Comparison
For the Medical Devices subindustry, Abbott Laboratories's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott Laboratories Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Abbott Laboratories's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Abbott Laboratories's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (XSWX:ABT) has a Equity-to-Asset of 0.47 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Abbott Laboratories and its competitors. This is near median its historical median of 0.47. Over the past decade, Abbott Laboratories' Equity-to-Asset has ranged from 0.39 to 0.61. According to the industry distribution chart, Abbott Laboratories ranks #596 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 70%.
Is Abbott Laboratories' Equity-to-Asset too high?
Abbott Laboratories' current Equity-to-Asset of 0.47 is near median its 10-year median of 0.47. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 0.61. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. Abbott Laboratories' value of 0.47 is 27.1% below this industry median. Based on the distribution chart, Abbott Laboratories ranks #596 out of 852 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Abbott Laboratories has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' Equity-to-Asset compare to SYK and MDT?
According to the Medical Devices & Instruments industry distribution chart, Abbott Laboratories ranks #596 out of 852 companies for Equity-to-Asset. This places Abbott Laboratories in the lower half of its industry. The industry median Equity-to-Asset is 0.65. Abbott Laboratories' value of 0.47 is 27.1% below this benchmark. Historically, Abbott Laboratories' own Equity-to-Asset has ranged from 0.39 to 0.61 over the past decade. While the company's 10-year median is 0.47 vs. the industry median of 0.65, Abbott Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbott Laboratories's current Equity-to-Asset of 0.47 is 27.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Abbott Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbott Laboratories's current Equity-to-Asset is 0.47, which is near median its own 10-year median of 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Abbott Laboratories (XSWX:ABT) has a current Equity-to-Asset of 0.47. The stock's GF Value™ is CHF107.34, compared to a current price of CHF84.50 — trading 21.3% below its estimated fair value. The current Equity-to-Asset is 0.47, which is near median its 10-year median of 0.47 and 27.1% below the Medical Devices & Instruments industry median of 0.65. Abbott Laboratories' overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Abbott Laboratories (XSWX:ABT), the current Equity-to-Asset is 0.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (XSWX:ABT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued.
The current stock price of CHF84.50 is trading 21.3% below its estimated GF Value™ of CHF107.34.
Key valuation signals for XSWX:ABT:
Equity-to-Asset: 0.47 (near median its 10-year median of 0.47)
GF Value™: CHF107.34 vs. price of CHF84.50 (21.3% below fair value)
Industry Position: 27.1% below the Medical Devices & Instruments median (#596 of 852)
No single metric tells the full story. See the XSWX:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
80GF Score
Get the complete analysis for XSWX:ABT
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ABT has been successfully added to your 
